Evidence map›Paper›PMID 25919850›Full record

ArticleThe Journal of clinical psychiatry2015

Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network.

Andrew A Nierenberg, Louisa Sylvia, Allen Doederlein, Susan Edgman-Levitan, Alies Muskin, Lucinda Jewell, Muffy Walker, Dan Goodman, Massoud Farahbakhsh, Casey Hearing and 2 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of clinical psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Andrew A NierenbergDepartment of Psychiatry, Massachusetts General Hospital, 50 Stanford St, 5th Floor, Boston, MA 02114 anierenberg@partners.org.
Louisa Sylvia
Allen Doederlein
Susan Edgman-Levitan
Alies Muskin
Lucinda Jewell
Muffy Walker
Dan Goodman
Massoud Farahbakhsh
Casey Hearing
Roberta Tovey
Thilo Deckersbach
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of JCP, Zhou and colleagues review and integrate placebo-controlled efficacy trials of medications for treatment-resistant depression (TRD) to compare efficacy in a meta-analysis. They conclude that, among 11 augmentation options for TRD, aripiprazole and quetiapine have the most robust evidence for efficacy, with the caveats that these treatments carry substantial risks of adverse events and no long-term data are available. In the absence of direct comparisons, this exercise highlights the formidable challenges that clinicians face when making decisions.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantFemaleHumansMajor Depressive DisorderMalePatient Acceptance of Health CareAntidepressive Agents

Identifiers

PMID25919850
OpenAlexW1998699936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.